SEPIDEH NIKBAKHT: Open Payments
NPI 1497112304 · KANSAS CITY, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$861 in 13 payments from 9 companies in 2025. Trend: 2023 $262 · 2024 $280 · 2025 $861
Food & beverage: $861
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 3 | $186 |
| Amgen Inc. | 1 | $130 |
| Astellas Pharma US Inc | 1 | $127 |
| SANOFI-AVENTIS U.S. LLC | 3 | $126 |
| Axsome Therapeutics, Inc. | 1 | $120 |
| Otsuka America Pharmaceutical, Inc. | 1 | $107 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Syndax Pharmaceuticals, Inc. | 1 | $20 |
| TAIHO ONCOLOGY, INC. | 1 | $20 |
Products named: VENCLEXTA, TEZSPIRE, Cresemba, REZUROCK, Auvelity, REXULTI, EPKINLY, LYNOZYFIC.
Industry payments across KS — which companies pay providers there.
